Big Money Sentiment decreased to 1 in 2018 Q4. It has change of 1.00, from 2018Q3’s 2. The ratio worsened due to CASI Pharmaceuticals, Inc. positioning: 10 sold and 15 reduced. 4 funds took holdings and 21 increased holdings. Investors holded 10.66 million in 2018Q3 but now own 11.34 million shares or 6.37% more.
Raymond James Fin Advsr invested in 0% or 60,090 shs. Ameriprise Fincl Inc has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 58,098 shs. California Employees Retirement Systems holds 0% or 139,600 shs. Morgan Stanley stated it has 84,427 shs. Natl Bank Of America Corp De reported 28,954 shs. Wellington Shields Cap Management Limited Com holds 0.89% or 1.18M shs in its capital. 22,528 are owned by Citadel Advisors Ltd Co. Voya Mngmt Limited Liability Corporation owns 21,893 shs. Goldman Sachs Grp has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Geode Management Limited Company owns 584,970 shs. Manufacturers Life Insur The invested in 31,943 shs or 0% of the stock. Jpmorgan Chase Company invested in 12,755 shs. The United Kingdom-based Legal And General Group Public Lc has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Alps owns 220,215 shs or 0.01% of their US capital. Invesco Ltd holds 0% or 13,303 shs.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI)’s quarterly earnings will be reported on April, 4., Zacks reports. Last year’s EPS was $-0.08, while now analysts expect change of 37.50 % up from current $-0.05 EPS. Wall Street now predicts -50.00 % EPS growth despite CASI Pharmaceuticals, Inc. previous quarter’s EPS of $-0.10. CASI touched $3.17 during the last trading session after $0.07 change.Currently CASI Pharmaceuticals, Inc. is downtrending after 5.48% change in last March 29, 2018. CASI has 117,173 shares volume. CASI underperformed the S&P500 by 9.85%.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China.The firm is valued at $302.06 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma.Currently it has negative earnings. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

More recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were posted by Prnewswire.com, Seekingalpha.com and Seekingalpha.com. The first one has “CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results – PRNewswire” as a title and was posted on March 29, 2019. The next is “Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics – Seeking Alpha” on March 17, 2019. And last was posted on March 13, 2019, called “CASI Pharma establishes Evomela distribution in China – Seeking Alpha”.